Metabolon Study Reveals Mechanisms of High Dosage Pentamethyl-6-Chromanol (PMCol) Toxicity in Liver Damage and Dysfunction

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec 8, 2011 - Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today the publication of “Toxicogenomics and Metabolomics of Pentamethylchromanol (PMCol)-Induced Hepatotoxicity” in the journal Toxicological Sciences. The study was conducted by the Biosciences Division of SRI International in conjunction with Metabolon scientists.

The study integrated classical toxicology, toxicogenomics, and metabolomic approaches to determine the mechanism of toxicity and identify sensitive early markers of target organ injury by PMCol.

Metabolomic evaluation of the liver and plasma samples found dose- and time-dependent effects, including depletion of total glutathione and glutathione conjugates, decreased methionine and cofactors FAD and NAD(P)+, and increased S-adenosylhomocysteine, cysteine, and cystine. Chronic exposure to high doses of PMCol induced liver damage and dysfunction that is likely due to two factors: the direct inhibition of glutathione synthesis and the modification of drug metabolism pathways.

The article has been published on-line in Toxicological Sciences and may be accessed by this link:

http://toxsci.oxfordjournals.org/content/early/2011/09/13/toxsci.kfr238.abstract

About Metabolon

Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry's leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon's expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or 919-595-2200.

 

Contact: LHA
Mackenzie Mills, 212-838-3777
mmills@lhai.com

 

 

Posted: December 2011

View comments

Hide
(web3)